InvestSMART

Cryosite Limited (ASX:CTE)

ALERT: Price-sensitive ASX Announcement for CTE
Current share price for CTE : $1.250 0 (0%)+
Announcement
Release
18 Aug 2026 4:43PM
Price at Release
$1.250
Full Release
download
Summary
The document is the 2026 Annual Report and Appendix 4E for Cryosite Limited, highlighting its financial performance and operational activities for the fiscal year ending on June 30, 2026. The company reported a total revenue of $16.7 million, an increase from the previous year's $14.1 million, with profits after tax amounting to $2.235 million. The report outlines segment information including revenue from ambient, cold, and frozen storage as well as ultra-frozen, cryogenic, and cord blood services. Key financial metrics include a total asset valuation of $25.971 million and liabilities amounting to $21.121 million. The document also covers the acquisition of a new warehouse property, funded through existing cash reserves and a new bank loan. Additionally, it discusses the issuance of share-based payments and provides insights into the remuneration of directors and key management personnel.
Key Points
  • Cryosite Limited's total revenue for 2026 was $16.7 million.
  • Profit after tax for the year was $2.235 million.
  • Revenue increase attributed to ambient, cold, frozen, ultra-frozen, cryogenic, and cord blood services.
  • Total assets valued at $25.971 million.
  • Total liabilities amounted to $21.121 million.
  • Acquisition of a new warehouse property funded by cash reserves and bank loan.
  • Share-based payments were issued during the year.
  • Remuneration details for directors and management were disclosed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.